/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Our investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder ( AUD ).
$4.86
$0.35 (-6.72%)
EOD Sep 18, 2026
Negative free cash flow of -$6M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$58M
▲ +39.6% YoY
Op. Margin
—
ROIC
-1350.18%
▲ +28.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$11M
▲ +6.2% YoY
Op. Cash Flow (TTM)
-$11M
▲ +6.2% YoY
Net Debt
-$29M
Net Cash Position
Cash & Equiv.
$29M
Continue Research
SourceComputed from the 10-Q filed 14 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 15 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.